- Molecular NameBortezomib
- Synonymbortezomib
- Weight384.244
- Drugbank_IDDB00188
- ACS_NO179324-69-7
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)1.07
- pkaN/A
- LogD (pH=7, predicted)0.45
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-3.83
- LogSw (predicted, AB/LogsW2.0)16.59
- Sw (mg/ml) (predicted, ACD/Labs)0.06
- No.of HBond Donors4
- No.of HBond Acceptors8
- No.of Rotatable Bonds9
- TPSA124.44
- StatusFDA approved
- AdministrationIntravenous
- PharmacologyThe first therapeutic proteasome inhibitor to be tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma[1] and mantle cell lymphoma.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability0.0
- Protein binding83.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic, CYP extensively involved
- Half life9 to 15 h
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityCardiovascular safety pharmacology studies in monkeys show that lethal IV doses are associated with decreases in blood pressure, increases in heart rate, increases in contractility, and ultimately terminal hypotension. In monkeys, doses of 3.0 mg/m2 and greater (approximately twice the recommended clinical dose) resulted in progressive hypotension starting at 1 hour and progressing to death by 12 to 14 hours following drug administration.
- LD50 (rat)N/A
- LD50 (mouse)N/A